{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:12:58Z","timestamp":1793812378794,"version":"4.6.1"},"reference-count":97,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"The Natural Science Foundations of Shandong Province","award":["ZR2020MH124"],"award-info":[{"award-number":["ZR2020MH124"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Multiple myeloma (MM) is a malignant hematological disease originating from plasma cells that remains incurable. Autologous stem cell transplantation (ASCT) is an important treatment method for MM. With the development of new drugs, the treatment of MM patients who meet the ASCT criteria has significantly improved, and the median survival time has increased by 8\u201310 years. The current treatment for MM patients who meet the ASCT criteria consists mainly of the following stages: induction therapy, stem cell collection, stem cell transplantation, and consolidation and maintenance therapy. Even today, long-term disease control remains the goal of MM treatment in clinical practice. In the era of new drugs, early ASCT still results in longer progression-free survival (PFS) and is currently the standard treatment method for young newly diagnosed multiple myeloma (NDMM) patients. Moreover, tandem transplantation can be considered for MM patients with high-risk cytogenetics. This review discusses mainly the role of ASCT in MM, the conditions for patient transplantation, the induction chemotherapy regimen before transplantation, the conditioning regimen, the timing of transplantation, and the effectiveness of tandem transplantation, including maintenance and salvage ASCT after transplantation.<\/jats:p>","DOI":"10.1177\/15330338251321349","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T18:46:30Z","timestamp":1742928390000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7550-2256","authenticated-orcid":false,"given":"Ya-Nan","family":"Wang","sequence":"first","affiliation":[{"name":"Shandong Provincial Hospital Affiliated to Shandong First Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-1954","authenticated-orcid":false,"given":"Chao-Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong Provincial Hospital Affiliated to Shandong First Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3341-415X","authenticated-orcid":false,"given":"Yu-Xuan","family":"Gao","sequence":"additional","affiliation":[{"name":"The Fifth People's Hospital of Jinan Affiliated to Shandong Second Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1420-6221","authenticated-orcid":false,"given":"Xue-Ling","family":"Ge","sequence":"additional","affiliation":[{"name":"Shandong Provincial Hospital Affiliated to Shandong First Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"issue":"11","key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple myeloma, version 2.2016: Clinical practice guidelines in oncology","volume":"13","author":"Anderson KC","year":"2015","unstructured":"Anderson KC, Alsina M, Atanackovic D, et al. Multiple myeloma, version 2.2016: Clinical practice guidelines in oncology. J Natl Compr Cancer Netw: JNCCN. 2015;13(11):1398-1435. doi:https:\/\/doi.org\/10.6004\/jnccn.2015.0167","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"issue":"11","key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3324\/haematol.2016.150334","article-title":"Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: A prospective multicenter study","volume":"101","author":"Garderet L","year":"2016","unstructured":"Garderet L, Beohou E, Caillot D, et al. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: A prospective multicenter study. Haematologica. 2016;101(11):1390-1397. doi:https:\/\/doi.org\/10.3324\/haematol.2016.150334","journal-title":"Haematologica"},{"issue":"26","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.2023022222","article-title":"Causes and consequences of clonal hematopoiesis","volume":"142","author":"Weeks LD","year":"2023","unstructured":"Weeks LD, Ebert BL. Causes and consequences of clonal hematopoiesis. Blood. 2023;142(26):2235-2246. doi:https:\/\/doi.org\/10.1182\/blood.2023022222","journal-title":"Blood"},{"issue":"14","key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael J","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228-1263. doi:https:\/\/doi.org\/10.1200\/jco.18.02096","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2020). Ann Oncol. 2021;32(3):309-322. doi:https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann Oncol"},{"issue":"2","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos MA","year":"2020","unstructured":"Dimopoulos MA, Jakubowiak AJ, McCarthy PL, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020;10(2):17. doi:https:\/\/doi.org\/10.1038\/s41408-020-0273-x","journal-title":"Blood Cancer J."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"issue":"1","key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang Y","year":"2020","unstructured":"Yang Y, Li Y, Gu H, Dong M, Cai Z. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13(1):150. doi:https:\/\/doi.org\/10.1186\/s13045-020-00980-5","journal-title":"J Hematol Oncol."},{"issue":"23","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot A","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456-2464. doi:https:\/\/doi.org\/10.1182\/blood-2018-06-858613","journal-title":"Blood"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3160"},{"issue":"5","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: Bringing the bench to the bedside","volume":"12","author":"Mailankody S","year":"2015","unstructured":"Mailankody S, Korde N, Lesokhin AM, et al. Minimal residual disease in multiple myeloma: Bringing the bench to the bedside. Nat Rev Clin Oncol. 2015;12(5):286-295. doi:https:\/\/doi.org\/10.1038\/nrclinonc.2014.239","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cyto.b.21273","article-title":"Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient","volume":"90","author":"Landgren O","year":"2016","unstructured":"Landgren O, Owen RG. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry B Clin Cytom. 2016;90(1):14-20. doi:https:\/\/doi.org\/10.1002\/cyto.b.21273","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00360-X","article-title":"Upfront autologous transplantation still improving outcomes in patients with multiple myeloma","volume":"10","author":"Beksac M","year":"2023","unstructured":"Beksac M, Hayden P. Upfront autologous transplantation still improving outcomes in patients with multiple myeloma. Lancet Haematol. 2023;10(2):e80-e82. doi:https:\/\/doi.org\/10.1016\/s2352-3026(22)00360-x","journal-title":"Lancet Haematol"},{"issue":"3","key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: A mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves WI","year":"2019","unstructured":"Gonsalves WI, Buadi FK, Ailawadhi S, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: A mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019;54(3):353-367. doi:https:\/\/doi.org\/10.1038\/s41409-018-0264-8","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","article-title":"Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma","volume":"19","author":"Costa LJ","year":"2013","unstructured":"Costa LJ, Zhang MJ, Zhong X, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013;19(11):1615-1624. doi:https:\/\/doi.org\/10.1016\/j.bbmt.2013.08.002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/bmt.2014.255","article-title":"Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: Increased use and improved outcomes in elderly patients in recent years","volume":"50","author":"Auner HW","year":"2015","unstructured":"Auner HW, Szydlo R, Hoek J, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: Increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50(2):209-215. doi:https:\/\/doi.org\/10.1038\/bmt.2014.255","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clml.2016.11.006","article-title":"Autologous hematopoietic cell transplantation in patients with multiple myeloma: Effect of age","volume":"17","author":"Dhakal B","year":"2017","unstructured":"Dhakal B, Nelson A, Guru Murthy GS, et al. Autologous hematopoietic cell transplantation in patients with multiple myeloma: Effect of age. Clin Lymphoma Myeloma Leuk. 2017;17(3):165-172. doi:https:\/\/doi.org\/10.1016\/j.clml.2016.11.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo A","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587-600. doi:https:\/\/doi.org\/10.1200\/jco.2013.48.7934","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_3_21_2","first-page":"249","article-title":"Therapy strategies for transplant candidates of multiple myeloma","volume":"19","author":"Huang WR","year":"2011","unstructured":"Huang WR, Yu L. Therapy strategies for transplant candidates of multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011;19(1):249-253.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"25","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: A pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta JJ","year":"2017","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: A pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol. 2017;35(25):2900-2910. doi:https:\/\/doi.org\/10.1200\/jco.2016.69.2517","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PPO.0000000000000348","article-title":"Optimizing immunomodulatory drug with proteasome inhibitor combinations in newly diagnosed multiple myeloma","volume":"25","author":"Ntanasis-Stathopoulos I","year":"2019","unstructured":"Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA. Optimizing immunomodulatory drug with proteasome inhibitor combinations in newly diagnosed multiple myeloma. Cancer J. 2019;25(1):2-10. doi:https:\/\/doi.org\/10.1097\/ppo.0000000000000348","journal-title":"Cancer J"},{"issue":"9","key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma","volume":"127","author":"Magarotto V","year":"2016","unstructured":"Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102-1108. doi:https:\/\/doi.org\/10.1182\/blood-2015-08-662627","journal-title":"Blood"},{"key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.critrevonc.2017.03.018","article-title":"Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: A meta-analysis of phase III randomized controlled trials","volume":"113","author":"Sun Z","year":"2017","unstructured":"Sun Z, Zheng F, Wu S, Liu Y, Guo H, Liu Y. Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: A meta-analysis of phase III randomized controlled trials. Crit Rev Oncol Hematol. 2017;113:249-255. doi:https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14656566.2017.1418856","article-title":"Triplet vs. Doublet drug regimens for managing multiple myeloma","volume":"19","author":"Offidani M","year":"2018","unstructured":"Offidani M, Corvatta L, Gentili S. Triplet vs. Doublet drug regimens for managing multiple myeloma. Expert Opin Pharmacother. 2018;19(2):137-149. doi:https:\/\/doi.org\/10.1080\/14656566.2017.1418856","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"e_1_3_3_27_2","first-page":"332","article-title":"Interpretation of minimal residual disease monitoring for response evaluation in \u201cthe guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)\u201d","volume":"59","author":"Chang YJ","year":"2020","unstructured":"Chang YJ, Chen SN. Interpretation of minimal residual disease monitoring for response evaluation in \u201cthe guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)\u201d. Zhonghua Nei Ke Za Zhi. 2020;59(5):332-334. doi:https:\/\/doi.org\/10.3760\/cma.j.cn112138-20200217-00084","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/11207510-000000000-00000"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"issue":"16","key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol L","year":"2019","unstructured":"Rosi\u00f1ol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337-1345. doi:https:\/\/doi.org\/10.1182\/blood.2019000241","journal-title":"Blood"},{"issue":"21","key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD Is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau P","year":"2016","unstructured":"Moreau P, Hulin C, Macro M, et al. VTD Is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial. Blood. 2016;127(21):2569-2574. doi:https:\/\/doi.org\/10.1182\/blood-2016-01-693580","journal-title":"Blood"},{"issue":"6","key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde N","year":"2015","unstructured":"Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1(6):746-754. doi:https:\/\/doi.org\/10.1001\/jamaoncol.2015.2010","journal-title":"JAMA Oncol."},{"issue":"10192","key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau P","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study. Lancet (London, England). 2019;394(10192):29-38. doi:https:\/\/doi.org\/10.1016\/s0140-6736(19)31240-1","journal-title":"Lancet (London, England)"},{"issue":"10","key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina A","year":"2020","unstructured":"Medina A, Puig N, Flores-Montero J, et al. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J. 2020;10(10):108. doi:https:\/\/doi.org\/10.1038\/s41408-020-00377-0","journal-title":"Blood Cancer J"},{"issue":"7","key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2020.247130","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson GH","year":"2021","unstructured":"Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica. 2021;106(7):1957-1967. doi:https:\/\/doi.org\/10.3324\/haematol.2020.247130","journal-title":"Haematologica"},{"issue":"12","key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar SK","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(12):1281-1301. doi:https:\/\/doi.org\/10.6004\/jnccn.2023.0061","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol L","year":"2012","unstructured":"Rosi\u00f1ol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA\/GEM study. Blood. 2012;120(8):1589-1596. doi:https:\/\/doi.org\/10.1182\/blood-2012-02-408922","journal-title":"Blood"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.26"},{"issue":"3","key":"e_1_3_3_39_2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2011.08949.x","article-title":"A comparison of lenalidomide\/dexamethasone versus cyclophosphamide\/lenalidomide\/dexamethasone versus cyclophosphamide\/bortezomib\/dexamethasone in newly diagnosed multiple myeloma","volume":"156","author":"Khan ML","year":"2012","unstructured":"Khan ML, Reeder CB, Kumar SK, et al. A comparison of lenalidomide\/dexamethasone versus cyclophosphamide\/lenalidomide\/dexamethasone versus cyclophosphamide\/bortezomib\/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol. 2012;156(3):326-333. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08949.x","journal-title":"Br J Haematol."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"issue":"22","key":"e_1_3_3_41_2","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau P","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118(22):5752-5758. https:\/\/doi.org\/10.1182\/blood-2011-05-355081","journal-title":"Blood"},{"issue":"8","key":"e_1_3_3_42_2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai EK","year":"2015","unstructured":"Mai EK, Bertsch U, D\u00fcrig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721-1729. doi:https:\/\/doi.org\/10.1038\/leu.2015.80","journal-title":"Leukemia"},{"issue":"7","key":"e_1_3_3_43_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.03.008","article-title":"Multiple myeloma: Clinical updates from the American society of hematology annual meeting 2018","volume":"19","author":"Terpos E","year":"2019","unstructured":"Terpos E, Ntanasis-Stathopoulos I. Multiple myeloma: Clinical updates from the American society of hematology annual meeting 2018. Clin Lymphoma Myeloma Leuk. 2019;19(7):e324-e336. doi:https:\/\/doi.org\/10.1016\/j.clml.2019.03.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"e_1_3_3_44_2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood.V128.22.1142.1142","article-title":"Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: Primary results of the intergroupe francophone du My\u00e9Lome (IFM) krd phase II study","volume":"128","author":"Roussel M","year":"2016","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, et al. Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: Primary results of the intergroupe francophone du My\u00e9Lome (IFM) krd phase II study. Blood. 2016;128(22):1142. https:\/\/doi.org\/10.1182\/blood.V128.22.1142.1142","journal-title":"Blood"},{"issue":"10","key":"e_1_3_3_45_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S1470-2045(21)00490-3","article-title":"Daratumumab for post-ASCT maintenance treatment of myeloma","volume":"22","author":"Kapoor P","year":"2021","unstructured":"Kapoor P, Kumar S. Daratumumab for post-ASCT maintenance treatment of myeloma. Lancet Oncol. 2021;22(10):1345-1347. doi:https:\/\/doi.org\/10.1016\/s1470-2045(21)00490-3","journal-title":"Lancet Oncol."},{"issue":"1","key":"e_1_3_3_46_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40364-024-00634-5","article-title":"Updates on CAR T cell therapy in multiple myeloma","volume":"12","author":"Nasiri F","year":"2024","unstructured":"Nasiri F, Asaadi Y, Mirzadeh F, et al. Updates on CAR T cell therapy in multiple myeloma. Biomark Res. 2024;12(1):102. doi:https:\/\/doi.org\/10.1186\/s40364-024-00634-5","journal-title":"Biomark Res."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0344"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909"},{"issue":"4","key":"e_1_3_3_49_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.15116","article-title":"Investigational agents in immunotherapy: A new horizon for the treatment of multiple myeloma","volume":"181","author":"Varga C","year":"2018","unstructured":"Varga C, Laubach JP, Anderson KC, Richardson PG. Investigational agents in immunotherapy: A new horizon for the treatment of multiple myeloma. Br J Haematol. 2018;181(4):433-446. https:\/\/doi.org\/10.1111\/bjh.15116","journal-title":"Br J Haematol."},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.013"},{"issue":"6","key":"e_1_3_3_51_2","first-page":"453","article-title":"Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: Long-term follow-up results from single center","volume":"40","author":"Wu Q","year":"2019","unstructured":"Wu Q, Liu JR, Huang BH, et al. Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: Long-term follow-up results from single center. Zhonghua Xue Ye Xue Za Zhi. 2019;40(6):453-459. doi:https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2019.06.002","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.096149"},{"issue":"1","key":"e_1_3_3_53_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13287-022-02802-6","article-title":"Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: A systematic review and network meta-analysis of randomized controlled trials","volume":"13","author":"Luo C","year":"2022","unstructured":"Luo C, Wu G, Huang X, et al. Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: A systematic review and network meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2022;13(1):123. doi:https:\/\/doi.org\/10.1186\/s13287-022-02802-6","journal-title":"Stem Cell Res Ther."},{"issue":"12","key":"e_1_3_3_54_2","first-page":"1003","article-title":"New agents-based induction chemotherapy followed by autologous stem cell transplantation and maintenance treatment strategy for multiple myeloma: A single center retrospective study of 300 cases","volume":"43","author":"Liu JR","year":"2022","unstructured":"Liu JR, Gu JL, Huang BH, et al. New agents-based induction chemotherapy followed by autologous stem cell transplantation and maintenance treatment strategy for multiple myeloma: A single center retrospective study of 300 cases. Zhonghua Xue Ye Xue Za Zhi. 2022;43(12):1003-1009. doi:https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2022.12.005","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"issue":"5","key":"e_1_3_3_55_2","first-page":"1525","article-title":"A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and \u2018on-demand\u2019 plerixafor in multiple myeloma patients treated with novel agents","volume":"109","author":"Mina R","year":"2024","unstructured":"Mina R, Petrucci MT, Bonello F, et al. A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and \u2018on-demand\u2019 plerixafor in multiple myeloma patients treated with novel agents. Haematologica. 2024;109(5):1525-1534. doi:https:\/\/doi.org\/10.3324\/haematol.2023.284023","journal-title":"Haematologica"},{"issue":"9","key":"e_1_3_3_56_2","first-page":"781","article-title":"Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in mobilization of autologous peripheral hematopoietic stem cells in patients with newly diagnosed multiple myeloma","volume":"43","author":"Li J","year":"2022","unstructured":"Li J, Zhang R, Chen LJ, et al. Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in mobilization of autologous peripheral hematopoietic stem cells in patients with newly diagnosed multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2022;43(9):781-784. doi:https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2022.09.012","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"5","key":"e_1_3_3_57_2","first-page":"353","article-title":"[Chinese guidelines of autologous stem cell transplantation for multiple myeloma (2021)]","volume":"42","year":"2021","unstructured":"[Chinese guidelines of autologous stem cell transplantation for multiple myeloma (2021)]. Zhonghua Xue Ye Xue Za Zhi. 2021;42(5):353-357. doi:https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2021.05.001","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3592"},{"issue":"8","key":"e_1_3_3_59_2","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.exphem.2006.06.003","article-title":"The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics","volume":"34","author":"Fruehauf S","year":"2006","unstructured":"Fruehauf S, Seeger T, Maier P, et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol. 2006;34(8):1052-1059. https:\/\/doi.org\/10.1016\/j.exphem.2006.06.003","journal-title":"Exp Hematol."},{"issue":"4","key":"e_1_3_3_60_2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2006.12.445","article-title":"Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD\/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor","volume":"13","author":"Hess DA","year":"2007","unstructured":"Hess DA, Bonde J, Craft TC, et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD\/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant. 2007;13(4):398-411. https:\/\/doi.org\/10.1016\/j.bbmt.2006.12.445","journal-title":"Biol Blood Marrow Transplant."},{"issue":"7","key":"e_1_3_3_61_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.exphem.2011.04.002","article-title":"Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34\u2009+\u2009cells mobilized by G-CSF and plerixafor","volume":"39","author":"Uchida N","year":"2011","unstructured":"Uchida N, Bonifacino A, Krouse AE, et al. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34\u2009+\u2009cells mobilized by G-CSF and plerixafor. Exp Hematol. 2011;39(7):795-805. https:\/\/doi.org\/10.1016\/j.exphem.2011.04.002","journal-title":"Exp Hematol."},{"issue":"4","key":"e_1_3_3_62_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bjh.15115","article-title":"How I manage red cell transfusions in patients with sickle cell disease","volume":"180","author":"Rees DC","year":"2018","unstructured":"Rees DC, Robinson S, Howard J. How I manage red cell transfusions in patients with sickle cell disease. Br J Haematol. 2018;180(4):607-617. https:\/\/doi.org\/10.1111\/bjh.15115","journal-title":"Br J Haematol."},{"issue":"6","key":"e_1_3_3_63_2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjh.18990","article-title":"Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma","volume":"202","author":"Asher S","year":"2023","unstructured":"Asher S, Shah R, Ings S, et al. Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma. Br J Haematol. 2023;202(6):1224-1227. https:\/\/doi.org\/10.1111\/bjh.18990","journal-title":"Br J Haematol."},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.323"},{"issue":"10","key":"e_1_3_3_65_2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2011.131","article-title":"Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy","volume":"25","author":"Cavallo F","year":"2011","unstructured":"Cavallo F, Bringhen S, Milone G, et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia. 2011;25(10):1627-1631. doi:https:\/\/doi.org\/10.1038\/leu.2011.131","journal-title":"Leukemia"},{"issue":"4","key":"e_1_3_3_66_2","first-page":"220","article-title":"Autologous stem cell transplantation in multiple myeloma","volume":"62","author":"Ricciuti G","year":"2020","unstructured":"Ricciuti G, Falcone A, Cascavilla N, Martinelli G, Cerchione C. Autologous stem cell transplantation in multiple myeloma. Panminerva Med. 2020;62(4):220-224. doi:https:\/\/doi.org\/10.23736\/s0031-0808.20.04114-2","journal-title":"Panminerva Med."},{"issue":"11","key":"e_1_3_3_67_2","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","article-title":"Busulfan 12\u2005mg\/kg plus melphalan 140\u2005mg\/m2 versus melphalan 200\u2005mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study","volume":"95","author":"Lahuerta JJ","year":"2010","unstructured":"Lahuerta JJ, Mateos MV, Mart\u00ednez-L\u00f3pez J, et al. Busulfan 12\u2005mg\/kg plus melphalan 140\u2005mg\/m2 versus melphalan 200\u2005mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study. Haematologica. 2010;95(11):1913-1920. doi:https:\/\/doi.org\/10.3324\/haematol.2010.028027","journal-title":"Haematologica"},{"issue":"1","key":"e_1_3_3_68_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbmt.2006.08.037","article-title":"Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-h dosing schedule","volume":"13","author":"Madden T","year":"2007","unstructured":"Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-h dosing schedule. Biol Blood Marrow Transplant. 2007;13(1):56-64. doi:https:\/\/doi.org\/10.1016\/j.bbmt.2006.08.037","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"e_1_3_3_69_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.33.7832","article-title":"Impact of the conditioning regimen in patients with multiple myeloma who undergo autologous transplantation","volume":"29","author":"de la Rubia J","year":"2011","unstructured":"de la Rubia J, Lahuerta JJ. Impact of the conditioning regimen in patients with multiple myeloma who undergo autologous transplantation. J Clin Oncol. 2011;29(15):e449; author reply e450. doi:https:\/\/doi.org\/10.1200\/jco.2010.33.7832","journal-title":"J Clin Oncol"},{"issue":"9","key":"e_1_3_3_70_2","first-page":"732","article-title":"High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma","volume":"40","author":"Gu JL","year":"2019","unstructured":"Gu JL, Li J, Liu JR, et al. High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2019;40(9):732-737. doi:https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2019.09.004","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"issue":"5","key":"e_1_3_3_71_2","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30023-7","article-title":"Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: An open-label, randomised, phase 3 trial","volume":"6","author":"Bashir Q","year":"2019","unstructured":"Bashir Q, Thall PF, Milton DR, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: An open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6(5):e266-e275. doi:https:\/\/doi.org\/10.1016\/s2352-3026(19)30023-7","journal-title":"Lancet Haematol."},{"issue":"1","key":"e_1_3_3_72_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the intergroupe francophone du my\u00e9lome (IFM)","volume":"115","author":"Roussel M","year":"2010","unstructured":"Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the intergroupe francophone du my\u00e9lome (IFM). Blood. 2010;115(1):32-37. doi:https:\/\/doi.org\/10.1182\/blood-2009-06-229658","journal-title":"Blood"},{"issue":"9","key":"e_1_3_3_73_2","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand JP","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92(9):3131-3136.","journal-title":"Blood"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2586"},{"issue":"8","key":"e_1_3_3_75_2","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/leu.2016.381","article-title":"Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis","volume":"31","author":"Gay F","year":"2017","unstructured":"Gay F, Oliva S, Petrucci MT, et al. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis. Leukemia. 2017;31(8):1727-1734. doi:https:\/\/doi.org\/10.1038\/leu.2016.381","journal-title":"Leukemia"},{"issue":"1","key":"e_1_3_3_76_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie B","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93(1):55-65.","journal-title":"Blood"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2509"},{"issue":"7","key":"e_1_3_3_79_2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3324\/haematol.11168","article-title":"Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: Long-term follow-up of the Dutch cooperative group HOVON 24 trial","volume":"92","author":"Sonneveld P","year":"2007","unstructured":"Sonneveld P, van der Holt B, Segeren CM, et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: Long-term follow-up of the Dutch cooperative group HOVON 24 trial. Haematologica. 2007;92(7):928-935. doi:https:\/\/doi.org\/10.3324\/haematol.11168","journal-title":"Haematologica"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0805626"},{"issue":"1","key":"e_1_3_3_81_2","first-page":"401","article-title":"Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: An analysis of phase 3 EMN02\/HO95 study","volume":"130","author":"Cavo M","year":"2017","unstructured":"Cavo M, Gay FM, Patriarca F, et al. Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: An analysis of phase 3 EMN02\/HO95 study. Blood. 2017;130(Supplement 1):401. doi:https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.401.401","journal-title":"Blood"},{"issue":"7","key":"e_1_3_3_82_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer EA","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37(7):589-597. doi:https:\/\/doi.org\/10.1200\/jco.18.00685","journal-title":"J Clin Oncol"},{"issue":"21","key":"e_1_3_3_83_2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood.V122.21.767.767","article-title":"Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: An integrated analysis of patient-level data from phase European III studies","volume":"122","author":"Cavo M","year":"2013","unstructured":"Cavo M, Salwender H, Rosi\u00f1ol L, et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: An integrated analysis of patient-level data from phase European III studies. Blood. 2013;122(21):767-767. doi:https:\/\/doi.org\/10.1182\/blood.V122.21.767.767","journal-title":"Blood"},{"issue":"8","key":"e_1_3_3_84_2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/bmt.2016.91","article-title":"Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy","volume":"51","author":"Gonsalves WI","year":"2016","unstructured":"Gonsalves WI, Rajkumar SV, Gertz MA, et al. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplant. 2016;51(8):1156-1158. doi:https:\/\/doi.org\/10.1038\/bmt.2016.91","journal-title":"Bone Marrow Transplant"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70245-1"},{"issue":"1","key":"e_1_3_3_86_2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2018-99-119762","article-title":"Subgroup analyses of the randomized GMMG phase III multicenter trial relapse suggest survival benefit of salvage autologous transplant primarily in low risk multiple myeloma","volume":"132","author":"Baertsch M-A","year":"2018","unstructured":"Baertsch M-A, Schlenzka J, Christina H, et al. Subgroup analyses of the randomized GMMG phase III multicenter trial relapse suggest survival benefit of salvage autologous transplant primarily in low risk multiple myeloma. Blood. 2018;132(Supplement 1):254. doi:https:\/\/doi.org\/10.1182\/blood-2018-99-119762","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_87_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2018-99-111203","article-title":"Salvage autologous transplant and lenalidomide maintenance versus continuous lenalidomide\/dexamethasone for relapsed multiple myeloma: Results of the randomized GMMG phase III multicenter trial relapse","volume":"132","author":"Goldschmidt H","year":"2018","unstructured":"Goldschmidt H, Baertsch M-A, Schlenzka J, et al. Salvage autologous transplant and lenalidomide maintenance versus continuous lenalidomide\/dexamethasone for relapsed multiple myeloma: Results of the randomized GMMG phase III multicenter trial relapse. Blood. 2018;132(Supplement 1):253. doi:https:\/\/doi.org\/10.1182\/blood-2018-99-111203","journal-title":"Blood"},{"issue":"7","key":"e_1_3_3_88_2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2018-08-825349","article-title":"Pros and cons of frontline autologous transplant in multiple myeloma: The debate over timing","volume":"133","author":"Kumar SK","year":"2019","unstructured":"Kumar SK, Buadi FK, Rajkumar SV. Pros and cons of frontline autologous transplant in multiple myeloma: The debate over timing. Blood. 2019;133(7):652-659. https:\/\/doi.org\/10.1182\/blood-2018-08-825349","journal-title":"Blood"},{"issue":"10","key":"e_1_3_3_89_2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance treatment and survival in patients with myeloma: A systematic review and network meta-analysis","volume":"4","author":"Gay F","year":"2018","unstructured":"Gay F, Jackson G, Rosi\u00f1ol L, et al. Maintenance treatment and survival in patients with myeloma: A systematic review and network meta-analysis. JAMA Oncol. 2018;4(10):1389-1397. doi:https:\/\/doi.org\/10.1001\/jamaoncol.2018.2961","journal-title":"JAMA Oncol"},{"issue":"12","key":"e_1_3_3_90_2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial","volume":"22","author":"Gay F","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22(12):1705-1720. doi:https:\/\/doi.org\/10.1016\/s1470-2045(21)00535-0","journal-title":"Lancet Oncol"},{"issue":"6","key":"e_1_3_3_91_2","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70229-2","article-title":"Lenalidomide maintenance for multiple myeloma","volume":"13","author":"Brower V","year":"2012","unstructured":"Brower V. Lenalidomide maintenance for multiple myeloma. Lancet Oncol. 2012;13(6):e238. doi:https:\/\/doi.org\/10.1016\/s1470-2045(12)70229-2","journal-title":"Lancet Oncol."},{"issue":"10","key":"e_1_3_3_92_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo A","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895-905. doi:https:\/\/doi.org\/10.1056\/NEJMoa1402888","journal-title":"N Engl J Med."},{"issue":"9","key":"e_1_3_3_93_2","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: A randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein SA","year":"2017","unstructured":"Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: A randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4(9):e431-e442. doi:https:\/\/doi.org\/10.1016\/s2352-3026(17)30140-0","journal-title":"Lancet Haematol."},{"issue":"15","key":"e_1_3_3_94_2","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2016.34.15_suppl.8001","article-title":"Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS)","volume":"34","author":"Attal M","year":"2016","unstructured":"Attal M, Palumbo A, Holstein SA, et al. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). J Clin Oncol. 2016;34(15_suppl):8001-8001. doi:https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.8001","journal-title":"J Clin Oncol."},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"issue":"1","key":"e_1_3_3_97_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00390-3","article-title":"Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma","volume":"11","author":"Baertsch MA","year":"2021","unstructured":"Baertsch MA, Mai EK, Hielscher T, et al. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2021;11(1):1. doi:https:\/\/doi.org\/10.1038\/s41408-020-00390-3","journal-title":"Blood Cancer J"},{"issue":"10168","key":"e_1_3_3_98_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos MA","year":"2019","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393(10168):253-264. doi:https:\/\/doi.org\/10.1016\/s0140-6736(18)33003-4","journal-title":"Lancet"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251321349","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338251321349","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251321349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:16:09Z","timestamp":1777702569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338251321349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":97,"alternative-id":["10.1177\/15330338251321349"],"URL":"https:\/\/doi.org\/10.1177\/15330338251321349","relation":{},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"article-number":"15330338251321349"}}